尿激酶联合巴曲酶治疗超早期脑梗死的效果研究

Clinical Efficacy of Urokinase in Combination with Defibrin in Treatment of Ultra-Early Cerebral Infarction

目的:观察尿激酶联合巴曲酶治疗超早期脑梗死的效果及不良反应。方法:选择超早期脑梗死60例,并经头颅CT或MR I证实无明显缺血病灶。采用简单随机法将60例分为3组,每组20例,分别给予尿激酶(Ⅰ组)、巴曲酶(Ⅱ组)、尿激酶联合巴曲酶(Ⅲ组)治疗,观察3组治疗1周、1个月、2个月的效果及不良反应。结果:2个月后Ⅲ组神经功能缺损评分明显低于Ⅰ组和Ⅱ组(P<0.05),Ⅰ组和Ⅱ组比较无明显差异(P>0.05)。结论:尿激酶联合巴曲酶治疗超早期脑梗死效果比单纯应用尿激酶或巴曲酶明显。

Objective：To observe the effect and side-effect of Urokinase in combination with with Defibrin in treatment of ultra-early cerebral infarction. Methods：Sixty patients with ultra-early cerebral infarction were selected and no visible ischemic focus were found in them by cranial CT and MRI. These subjects were divided randomly to 3 groups with 20 in each, The first group was given Urokinase 1M U a day;the second was given Defibrin;the third group received the combined scheme of Urokinase and Defibrin. The effecacy and side effect were observed and evaluated in the three groups after 1 week, 1 month and 2 months of the treatment schemes. Results ：After 2 months, nerve injury score was significantly lower in the the third group than in the first and second groups （ P 〈 0. 01 ） ; there was no significant differece between the first and second groups. Conclusion ： The administration of Urokinase in combination with Defibrin produced a better efficacy in comparison with either Urokinase or Defibrin alone.